MT-TL1 and Stroke: In a consensus statement from the mitochondrial medicine society (MMS) regarding patient care standards for primary mitochondrial disease that was based on Delphi-consensus, it was stated that “IV arginine hydrochloride should be administered urgently in the acute setting of a stroke-like episode associated with the MELAS m.3243 A > G mutation in the MT-TL1 gene and considered in a stroke-like episode associated with other primary mitochondrial cytopathies as other etiologies are being excluded.